


- Immuno-PCR: Maximizing Immunoassay Performance -

Ron Wacker

Chimera Biotec GmbH, Emil-Figge-Str. 76a, 44227 Dortmund, Germany, Phone +49 231 9742 840, Fax +49 231 9742 844, wacker@chimera-biotec.com




The Immuno-PCR is an innovative biomarker detection and monitoring technology focused on the analysis of low abundant and hardly detectable biomarkers. It combines the advantages of immunoassays with the exponential signal amplification of PCR.

The Imperacer™ product & service line enables the establishment of Immuno-PCR assays for any protein target.

**Imperacer™ Key Advantages:**

- typically 1000-fold increase in immunoassay sensitivity (LOD)
- high tolerance against drug and biological sample effects
- minimized sample volume (SV)
- broad dynamic range of quantification (QR)

Imperacer™ can be used for any protein target



The Immuno-PCR technology has already been used successfully for a large range of applications, including pharmacokinetic studies, cytokine analysis, early detection of biomarkers, viral protein detection, and many more. In the future Immuno-PCR utilizing Imperacer™ will enable an almost unlimited range of new assays for innovative biomarkers.

References:

[1] Niemeyer, C.M., Adler, M., Wacker, R., Immuno-PCR: high sensitivity detection of proteins by nucleic acid amplification, Trends Biotechnol., 23(4), p. 208-16, 2005.  
 [2] Niemeyer, C.M., Adler, M., Wacker, R., Detecting antigens by quantitative immuno-PCR, Nature Protocols, 2(8), p. 1918-1930, 2007.